These findings revealed that several biomarkers, particularly fibronectin, pAkt, pErk, pStat3, pAMPK, HMGA1, and IGF2BP1, exhibited significant differences in expression based on the pAXL status in patients with GC. This evidence concerns the gene IGF2BP1 and gastric cancer.